You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Unichem Labs spurts on USFDA nod for psoriasis drug

Capital Market 

Unichem Laboratories surged 5.71% to Rs 323.05 after the company received United States Food and Drug Administration (USFDA) approval for apremilast tablets, 10 mg, 20 mg and 30 mg.

The drug is a generic version of Amgen's Otezla (apremilast) tablets, 10 mg, 20 mg, and 30 mg.

The drug is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

The scrip extended gains for third day. The stock has added 6.67% in three sessions from its recent closing low of Rs 302.85 recorded on 16 February 2021.

In the past three months, the stock has added 36.73% while the benchmark Sensex has added 17.55% during the same period.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.

The company reported a consolidated net profit of Rs 23.56 crore in Q3 FY21 as compared to a net loss of Rs 14.60 crore in Q3 FY20. Net sales during the quarter increased by 18.7% YoY to Rs 326.28 crore.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 19 2021. 12:16 IST